Janssen Research and Development - Articles and news items

Janssen Pharmaceuticals Logo

Janssen investigational treatment for schizophrenia shows positive efficacy, delays relapse

Industry news / 20 March 2014 / Johnson & Johnson

Independent data monitoring committee recommends halting trial and unblinding data based on treatment efficacy…

Janssen Pharmaceuticals Logo

Independent data monitoring committee recommends early stopping of Phase 3 study of Ibrutinib in relapsed/refractory CLL/SLL patients based on a planned interim analysis

Industry news / 7 January 2014 / Johnson & Johnson

“We’re delighted with this outcome, and look forward to sharing these results with the scientific community and Health Authorities…”

Janssen Pharmaceuticals Logo

New data at American Society of Hematology (ASH) Annuaul Meeting will offer important insights into safe and efficacious use of XARELTO®

Industry news / 3 December 2013 /

XARELTO® is the most prescribed novel oral anticoagulant in the U.S. Market today…

Janssen Pharmaceuticals Logo

New two-year results show SIMPONI® ARIA™ (GOLIMUMAB) for infusion inhibited radiographic progression in patients with active rheumatoid arthritis

Industry news / 28 October 2013 / Johnson & Johnson

Nearly 70 percent of patients receiving SIMPONI ARIA at two years demonstrated ACR 20 response…

Johnson & Johnson logo

FDA Advisory Committee recommends approval of Simeprevir for combination treatment of genotype 1 chronic hepatitis C in adult patients

Industry news / 24 October 2013 / Johnson & Johnson

Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously to recommend approval of the investigational protease inhibitor simeprevir…

Johnson & Johnson logo

Simeprevir Data from COSMOS study in Hepatitis C Patients accepted as late-breaking presentation at the annual meeting of the American Association for the Study of Liver Diseases (AASLD)

Industry news / 8 October 2013 / Johnson & Johnson

Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells…

Janssen Pharmaceuticals Logo

Latest Phase 3 Results demonstrate safety profile of INVOKANA® (canagliflozin) as add-on therapy in the treatment of Type 2 Diabetes

Industry news, News / 24 September 2013 / Janssen Research & Development, LLC

In patients inadequately controlled on metformin and a sulfonylurea, study results suggest canagliflozin improves glycemic control and was generally well tolerated, compared to placebo…

Janssen Pharmaceuticals Logo

Simultaneous applications submitted to FDA and EMA for siltuximab for the treatment of MCD, a rare blood disorder

Industry news, News / 3 September 2013 / Johnson & Johnson

“We’re proud of our work on siltuximab. As a rare disease with a small patient population, MCD is an area of significant unmet need”

Janssen Pharmaceuticals Logo

Janssen Research & Development announces establishment of global cross-pharmaceutical clinical trial Investigator Databank

Industry news, News / 15 November 2012 / Janssen Global Services

Lilly and Merck are first to join Janssen in this pre-competitive initiative to increase efficiencies in clinical trials…

Pfizer logo

Pfizer announces co-primary clinical endpoints not met in second Phase 3 Bapineuzumab Study

Industry news, News / 6 August 2012 / Pfizer

Bapineuzumab IV Phase 3 program discontinued…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...